- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
Dynavax seeks supplemental FDA filing for adults.
1 report, 1 independent
Updated Sep 2
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Dynavax seeks supplemental FDA filing for adults.
Who's involved
What this event is mainly aboutKeep exploring
Part of
A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.Also in this story
- A partnership with BARDA has accelerated the development of SCY-247 for the company.
- A company plans to submit regulatory applications to the FDA, EMA, and Australian TGA.
- Approval leads to procurement process initiation.
- UroGen Pharma Ltd., headquartered in Princeton, is seeking FDA approval for its products for the U.S. market.
The entities involved
- FDA
-
Dynavax Technologies (United States)
company in Berkeley, United States
Nothing else this week.
Related events
- Qiagen received FDA clearance for its diagnostic product, QIAstat-Dx Rise, expanding access in the U.S. on September 3, 2025.
- A bill has been introduced that seeks FDA evaluation for new therapies, specifically endorsing legislation focused on veteran care.
- A study protocol involving a company based in Mont-Saint-Guibert was approved by the U.S. FDA.
- The FDA requested additional clinical data from Unicycive Therapeutics.
Coverage
Newest first; wire copies grouped- Insider MonkeyDynavax Technologies Corporation (DVAX) Reports Record $92M HEPLISAV-B Revenue, Raises 2025 Outlook We recently compiled a list of the 11 Best Pharma Stocks to Invest in for the Long Term. Dynavax Te